What is RIGL's market cap?

$958.09M, based on the Nov 4 close of $51.29.

What is RIGL's P/E ratio?

3.0× trailing-twelve-month earnings of $321.91M.

Does Rigel Pharmaceuticals Inc. (New) pay a dividend?

No regular cash dividend has been paid in the last year.

How much of RIGL is sold short?

2.7M shares, 16.3% of float, as of Oct 15, 2026.

What sector is RIGL in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · RIGLHealthcarePharmaceuticals

Rigel Pharmaceuticals Inc. (New) (RIGL)

$51.29+4.97%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$51.29▲ 80.73% in range

Nov 4, 2025Low $25.44 · High $51.45Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Rigel Pharmaceuticals Inc. (New) closed at $51.29 on Nov 4, up 4.97%, 0.3% below its 52-week closing high. Volume of 288.8K shares was 1.46× its 20-day average (above normal).

Split-adjusted performance: +11.2% over one month, +92.3% over six months, +67.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $78.70M, down 22.6% from a year earlier, with a net margin of 22.0%.

Short interest was 2.7M shares at the Oct 15 settlement, down 4.3% from the prior report (16.3% of float, 12.8 days to cover).

Market cap$958.1M18.7M shares

Revenue · quarter$78.7M−22.6% YoY

Diluted EPS$0.88−73.2% YoY

P/E · TTM3.0×P/S 3.5×

Net margin22.0%Gross 89.2%

Dividend yieldNone

52-week range25.44 – 51.45−0.3% from high

Volume288.8K1.46× 20-day avg

Volatility · 60d37.8%Annualised

Short % of float16.3%12.8 days to cover

Net cash$56.1MCash $95.3M

Next earnings—Not scheduled

Split-adjusted performance

1W +1.1%1M +11.2%3M +30.8%6M +92.3%YTD +19.8%1Y +67.3%3Y +557.2%5Y +56.9%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum98

Revenue growth28

Net margin86

Value (low P/E)93

Size70

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short2.7M−4.3% vs prior

Days to cover12.8Settled Oct 15

% of float16.3%

Short vol. 10d54.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
RIGLRigel Pharmaceuticals Inc. (New)	$51.29	+4.97%	+92.3%	−22.6%	22.0%	3.0	$958.1M
SVRASavara	$4.66	−1.89%	−11.6%	—	—	—	$957.4M	Compare
JBIOJade Biosciences	$15.04	+3.23%	−40.2%	—	—	—	$956.5M	Compare
ORICOric Pharmaceuticals	$9.34	−2.61%	+0.4%	—	—	—	$968.1M	Compare
SNDXSyndax Pharmaceuticals	$10.45	−26.87%	−49.4%	+81.6%	−59.3%	—	$933.2M	Compare
MLTXMoonLake Immunotherapeutics	$11.56	−1.20%	−34.7%	—	—	—	$983.8M	Compare
LTGOLatigo Biotherapeutics	$14.04	−3.64%	—	—	—	—	$930.8M	Compare
ANROAlto Neuroscience	$23.30	+2.64%	−4.9%	—	—	—	$914.3M	Compare
CRVSCorvus Pharmaceuticals	$10.57	+7.53%	−31.6%	—	—	—	$889.2M	Compare

News about Rigel Pharmaceuticals Inc. (New)

All news →

Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in ColombiaGlobeNewswire Inc. · Sep 1, 2026▲ Positive Thérapeutique Knight annonce l’approbation réglementaire de TAVALISSE® en ColombieGlobeNewswire Inc. · Sep 1, 2026▲ Positive Onco360® Has Been Selected as a National Pharmacy Partner for VEPPANU™ (vepdegestrant)GlobeNewswire Inc. · Jul 29, 2026▲ Positive Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, PfizerBenzinga · May 12, 2026▲ Positive

Quick answers

What does Rigel Pharmaceuticals Inc. (New) do?: Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca.
What is RIGL's market cap?: $958.09M, based on the Nov 4 close of $51.29.
What is RIGL's P/E ratio?: 3.0× trailing-twelve-month earnings of $321.91M.
Does Rigel Pharmaceuticals Inc. (New) pay a dividend?: No regular cash dividend has been paid in the last year.
How much of RIGL is sold short?: 2.7M shares, 16.3% of float, as of Oct 15, 2026.
What sector is RIGL in?: Healthcare, in the Pharmaceuticals industry.

About Rigel Pharmaceuticals Inc. (New)

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

HQ: South San Francisco, CA174 employeesListed Nov 29, 2000rigel.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology